Eastern Bank’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$35.5K Buy
57
+13
+30% +$8.85K ﹤0.01% 669
2026
Q1
$34K Buy
44
+14
+47% +$10.7K ﹤0.01% 633
2025
Q4
$23.2K Buy
30
+20
+200% +$13.6K ﹤0.01% 701
2025
Q3
$5.62K Sell
10
-15
-60% -$8.48K ﹤0.01% 895
2025
Q2
$13.1K Hold
25
﹤0.01% 730
2025
Q1
$15.9K Buy
25
+5
+25% +$3.44K ﹤0.01% 727
2024
Q4
$14.2K Hold
20
﹤0.01% 735
2024
Q3
$21K Buy
+20
New +$22.3K ﹤0.01% 677

Other funds holding REGN

Eastern Bank's REGN Position: Q2 2026 in Review

Eastern Bank increased its Regeneron Pharmaceuticals (REGN) stake by 30% in Q2 2026, buying an estimated $8.85K and bringing the position to 57 shares worth $35.5K. The position accounts for ﹤0.01% of the portfolio, ranked #669.

Eastern Bank first reported a position in REGN in Q3 2024 and has held it in 8 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Eastern Bank held 57 shares of Regeneron Pharmaceuticals worth $35.5K as of Q2 2026.
  • Eastern Bank bought 13 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $8.85K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Eastern Bank's portfolio in Q2 2026, its #669 holding.
  • Eastern Bank first reported a position in Regeneron Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Eastern Bank's 13F filing for Q2 2026, filed 1 Jul 2026.